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Abstract 
Pancreatic cancer consists of an accumulation of genetic and epigenetic alterations. Recently, aberrant methylation of CpG islands of 
cancer-related genes has emerged as an important epigenetic mechanism of their transcriptional dysregulation during tumour 
development [1]. Therefore, new diagnostic methods, for early detection based on a better understanding of the molecular biology of 
pancreatic cancer, are required. We examined the methylation status of p
16INK4A, RASSF 1A and methylguanine methyltransferase 
(MGMT) genes considered to be inactivated by promoter methylation in several tumours. 
The p
16INK4A is an important G1/S cell cycle regulator gene [2]. RASSF 1A gene is involved in apoptotic signalling, microtubule 
stabilization and cell cycle progression [3]. The MGMT gene removes mutagenic and cytotoxic alkyl-adducts from the O6-position of 
guanine in DNA. Hypermethylation of the gene leads to the inactivation of DNA repair and to microsatellite instability [4]. 
To date, little is known about the exact role of hypermethylation of these genes in pancreatic adenocarcinoma, as the molecular 
mechanisms underlying these neoplasms remain poorly understood. 
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Figure 1: MSP analysis of p
16INK4A on agarose gel. All samples were run with both PCR products for unmethylated and methylated portions. The 
presence of a visible PCR product in these lanes marked U indicates the presence of unmethylated alleles; the presence of product in these 
lanes marked M indicates the presence of methylated alleles. In this electrophoresis, all patients presented hypermethylation of p
16INK4A 
promoter region. Primer set for U p
16INK4A: Sense primer 5'-TTATTAGAGGGTGGGGTGGATTGT-3', Antisense primer 5'-
CAACCCCAAACCACAACCATAA-3'. Primer set for M p
16INK4A : Sense primer 5'-TTATTAGAGGGTGGGGCGGATCGC-3', Antisense primer 5'-
GACCCCGAACCGCGACCGTAA-3'.
Materials and methods 
Tumour specimens from 13 patients with pancreatic 
adenocarcinoma (male/female: 8/5, mean age 67.2 years, 
range 54–79) were evaluated for the methylation status of 
p
16INK4A, RASSF 1A and MGMT genes. 
Genomic DNA was extracted from formalin-fixed paraffin-
embedded tumour tissues. 
DNA methylation was determined by chemical modification of 
genomic DNA with sodium bisulfite and subsequent a double 
‘hot start’ methylation-specific polymerase chain reaction 
(MSP). MSP has been designed to distinguish methylated from 
unmethylated DNA. ‘Hot start’ polymerase chain reaction (PCR) 
permits the Taq polymerase to begin the reaction only after the 
template and primers are in single-stranded form. 
All double MSPs were performed with controls for unmethylated 
and methylated alleles and a control with H2O. Ten microlitres of 
each second MSP reaction were directly loaded onto 2% 
agarose, stained with ethidium bromide and visualized under 
UV illumination. The presence of a visible MSP product in those 
lanes marked M indicated the presence of methylated alleles. 
The results on promoter methylation of all genes were 
correlated with known clinicopathological parameters. 
 
Results 
The p
16INK4A gene was methylated in all 13 patients (Figure 1). 
RASSF 1A was methylated in two patients, while the MGMT 
gene was methylated only in the patient with poorly 
differentiated pancreatic adenocarcinoma (Figure 2). The same 
patient has also methylated and the RASSF 1A gene. Lymph
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Figure 2: MSP analysis of O6-MGMT gene. All samples were run with both PCR products for unmethylated and methylated portions. The 
presence of a visible PCR product in these lanes marked U indicates the presence of unmethylated alleles; the presence of product in these 
lanes marked M indicates the presence of methylated alleles. In the present electrophoresis, the patient in lane 14M presented 
hypermethylation of O6-MGMT promoter region. Primer set for U O6-MGMT: Sense primer 5- TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3', 
Antisense primer 5'-AACTCCACACTCTTCCAAAAACAAAACA-3'. Primer set for M O6-MGMT: Sense primer 5'-TTTCGACGTTCGTAGGTTTTCGC-
3', Antisense primer 5'-GCACTCTTCCGAAAACGAAACG-3'.
node status did not correlate with methylation of gene 
promoters in pancreatic adenocarcinoma patients. 
 
Conclusions 
MSP provides a positive, sensitive (detection 1 methylated 
allele in a background of 1000 unmethylated alleles), quick and 
cost-effective test to analyse methylation status of CpG 
dinucleotides in a CpG island, making the technique suitable for 
high-throughput analysis of clinical samples. Our findings
suggest that p
16INK4A gene is commonly down-regulated in 
pancreatic adenocarcinoma through a promoter 
hypermethylation of CpG islands. Of course, the small group of 
13 analysed patients does not allow us to support the exact role 
of hypermethylation of RASSF 1A and/or MGMT on pancreatic 
cancer, yet. To this point, further studies with more patients are 
now carried out in our lab in order to assess if these epigenetic 
alterations provide additional information regarding to 
pancreatic adenocarcinoma prognosis and finally offer 
additional parameters for potential biological therapeutic 
strategies of this aggressive disease.
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